Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Jupiter Neurosciences lists on Nasdaq following $11 million IPO
Jupiter Neurosciences (NASDAQ: JUNS) has listed on the Nasdaq following a successful $11 million raise through its initial public offering (IPO). The company offered 2,750,000 shares of common stock at a price of $4.00 per share. Dominari Securities served as the lead underwriter for the offering, with Revere Securities acting as co-manager. Use of IPO […]
Latest Stories
Poolbeg Pharma moves closer to granting of patent for POLB 001 to treat multiple diseases
UK biopharmaceutical company Poolbeg Pharma (OTCQB: POLBF) has received a notice of allowance from the US Patent Office in relation to an application for its lead candidate POLB 001 in the treatment of multiple diseases. The notice covers a class of drugs (including POLB 001) for treating hypercytokinaemia (cytokine storm) and for preventing its development […]
Radiopharm Theranostics advances cancer treatment with RAD 301 and RAD 302 developments
Radiopharm Theranostics (ASX: RAD) has welcomed the release of new data identifying a promising pathway for its innovative RAD 301 and RAD 302 oncology developments. Multiple new data covering the RAD 301 and RAD 302 programs were featured at the 2024 European Molecular Imaging Meeting (EMIM) in Portugal this week. RAD 302, which is currently […]
Incannex releases groundbreaking results from psilocybin trial to treat anxiety, moves to Phase 2b FDA trials
Cannabinoid and psychedelic medicine biotechnology company Incannex Healthcare (NASDAQ: IXHL) has announced positive top-line results from its Phase 2 Psi-GAD1 clinical trial of psilocybin for the treatment of generalised anxiety disorder (GAD). The trial of the seven week treatment program was developed by Incannex in partnership with the Clinical Psychedelic Lab at Melbourne’s Monash University […]
Immutep doses first patient in Phase II/III efti trial to treat metastatic breast cancer
Biotechnology company Immutep (ASX: IMM) has safely dosed the first patient at a European clinical site for its integrated Phase II/III AIPAC-003 trial to treat metastatic breast cancer. AIPAC-003 is evaluating the company’s soluble LAG-3 protein and first-in-class MHC Class II agonist known as eftilagimod alpha (efti) in combination with standard-of-care paclitaxel for the treatment […]
Incannex commences phase 2 trial assessing IHL-675A for treatment of rheumatoid arthritis
Medicinal cannabinoid and psychedelic therapies developer Incannex Healthcare (ASX: IHL) has commenced a phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients with rheumatoid arthritis. The trial is being managed by Avance Clinical and will engage up to 10 sites across Australia and New Zealand, […]
StageZero Life Sciences launches updated care oncology protocol for enhanced cancer treatment
Cancer research company StageZero Life Sciences (OTC: SZLSF) has launched an update to its proprietary care oncology (COC) protocol which uses advanced biomarker testing and an interactive digital health platform to make an enhanced connection between a patient’s metabolic health and cancer outcomes. Research has shown metabolically-targeted drugs have promise as an adjunctive therapy to […]
Incannex Healthcare to benefit from landmark TGA decision on psychedelics
The Therapeutic Goods Administration (TGA) has announced that from 1 July 2023, medicines containing psilocybin and MDMA can be prescribed by authorised psychiatrists. In an announcement made on Friday, the TGA stated it will permit the prescribing of psilocybin for treatment-resistant depression (TRD) and MDMA for the treatment of post-traumatic stress disorder (PTSD). For these […]
Genetic Technologies to launch world-first comprehensive risk assessment test for breast and ovarian cancer
A ground-breaking comprehensive risk assessment test is set to be introduced by Genetic Technologies (ASX: GTG) to assesses the likelihood that a woman will develop breast and/or ovarian cancer, whether as a result of a hereditary genetic mutation or the much more prevalent familial or sporadic cancer. The test integrates Genetic Technologies’ patented and proprietary GeneType platform […]
Incannex Healthcare files new patent application for IHL-42X to treat obstructive sleep apnea
Medcan and psychedelic pharmaceutical company Incannex Healthcare (NASDAQ: IXHL) has filed a provisional patent application directed to the use of lead drug IHL-42X for the treatment of obstructive sleep apnea (OSA). The application is the latest in the company’s ongoing commercial strategy to accrue a series of patent families across the development, manufacture and use […]
Walgreens-backed VillageMD to buy Summit Health
Walgreens (NASDAQ: WBA) majority-owned VillageMD has announced it is acquiring Summit Health-CityMD to create one of the largest independent provider groups in the US. The deal announced on Monday is worth US$8.9 billion, and will expand the nation’s second-largest pharmacy store chain Walgreen’s reach into primary, specialty and urgent care. Together, VillageMD and Summit Health-CityMD […]
Pacific Biosciences announces launch of two new gene-sequencing systems
US biotech company Pacific BioSciences of California (PacBio) (NASDAQ: PACB) has joined a number of next-generation sequencing (NGS) launches this year, having announced its own upcoming release of two new sequencing systems. The California-based company announced the news at the American Society of Human Genetics (ASHG) conference, suggesting the new gene-sequencing systems were more affordable […]